Francis (Frank) Farraye, MD, MSc

Welcome @guthealingg Dr. Sophia Dar to @MayoClinicFLGIH as the 2026-2027 5th Advanced #IBD Fellow Welcome to the @MayoClinicGIHep family 🧑‍🧑‍🧒‍🧒 @FarrayeIBD @JHashashMD @JGubatanMD

Thank you @DDS_Journal for highlighting our work on BAS & pouchitis @AlsakarnehSaqr @FarrayeIBD ✅BAS not inferior to abx in nonresponse or early relapse (aOR=0.94, p=0.34) ✅ BAS ⬇️ recurrent pouchitis (aHR: 0.57; p<0.001) and ⬆️ time to recurrent pouchitis (p<0.001)

Our #IBD group is growing under @FarrayeIBD leadership Welcome Dr. John Gubatan @JGubatanMD joining @MayoClinicFLGIH family from Standford where he served as #IBD faculty

Gaining the Upper Hand – Upadacitinib for Crohn’s Disease with Ileostomy: A Real-World Gap Addressed. rdcu.be/eARJX . My invited commentary on doi.org/10.1007/s10620…, just published in @DDS_Journal. @LaurenLoebMD @FarrayeIBD @EdwardLoftus2 @ibdgijami @JHashashMD

Join us for our 2nd @Mayoclinic #IBD Conference in ☀️🏖️ Florida 🐊 @MayoClinicFLGIH 📍Mayo FL 🗓️ Saturday, Nov 8 💻 Virtual option available ➕🩻 bonus Friday session with ✋🤚 on IUS session 📝👉 tinyurl.com/3emuhwpv @FarrayeIBD @ibdgijami @JGubatanMD @CrohnsColitisFn

🩺💉 New @AmCollegeGastro guideline urges GI docs to promote preventive care — like vaccines & screenings — for #IBD patients.   Many patients see their GI as a de facto #PrimaryCare provider, say @FarrayeIBD & colleagues. #PreventiveCare #GITwitter bit.ly/44tkyHv

Patients with Crohn’s Disease and Ileostomy Can Respond to Upadacitinib | Digestive Diseases and Sciences ⁦@LaurenLoebMD⁩ ⁦@ibdgijami⁩ ⁦@ibdgijami⁩ ⁦@JHashashMD⁩ ⁦@FarrayeIBD⁩ link.springer.com/article/10.100…

Such a pleasure to host Francis A. Farraye, MD, MSc, today for GI Grand Rounds as we celebrated our fourth annual Peppercorn Lectureship, named for Dr. Mark Peppercorn! We all enjoyed learning from Dr. Farraye's talk, "Health Maintenance for Patients with IBD." 🌟

Hot of the press 🚨 Just published in @APandT our study on risk of new onset #IBD in patients taking IL-17 inhibitors 💊 🔑 findings: 📌 Patients on anti-IL-17 are at increased risk of de novo IBD (aHR: 2.5) 📌 Risk was elevated for both UC and CD 📌Number needed to harm (NNH=161) 📌Secukinumab was associated with highest risk (aHR=2.82) Full 📖: onlinelibrary.wiley.com/doi/10.1111/ap… @FarrayeIBD @JHashashMD @OmarAlTaanii @RazanAburummann @AmCollegeGastro @AmerGastroAssn @CrohnsColitisFn @ACPIMPhysicians @ACRheum #GITwitter #MedTwitter

Incredibly high yield topic on everyday IBD in terms of things to monitor in patients with IBD! @DCharabaty @FarrayeIBD @PDulaiMD @IBDConference #AIBD2024

🔥New article published in @AmJGastro 📈 IBD incidence is surging disproportionately affecting females and the elderly ⬆️ 75% of countries report rising incidence rates shorturl.at/GL4pn @FarrayeIBD @KarnJUVE @Siew_C_Ng @RashidLui @GKochharMD @ChawinthornV @ttuhscmed

💡 Key Question: Are patients with IBD at higher risk for shingles complications? (Spoiler: Yes!) 📊 What We Found: IBD patients had 15.52% complication rate vs 12.51% in non-IBD controls (p<0.0001) 4/12 @IBDProNews @CrohnsColitisFn @FarrayeIBD

New Clinical Practice Update in @AGA_CGH by Drs. Anna M. Buchner, @MariettaIacucci, and @FarrayeIBD explores using endoscopic scoring systems for mucosal healing for patients with #IBD, including ulcerative colitis and #Crohn's disease. 🔗Learn more: ow.ly/WawU50U7b8W

#IBD patients want to know… What they can do in addition to starting effective medical therapy for their inflammation 🚭 avoid smoking 🍽️Diet: Mediterranean diet 🍆🥑🍓🥦 🚫NSAID 🎯Normal BMI 🏃🏽‍♀️Get active 😊Focus on mental health 👶Discuss contraception @AshwinMDIBD

Save the date!! Sept 28, 2024! For Updates in IBD conference @MayoClinic FL Great topics Amazing speakers Sun and Fun Sign up ce.mayo.edu/ibd2024 @AmCollegeGastro @AmerGastroAssn @CrohnsColitisFn @IBDProNews @FarrayeIBD @ibdgijami @EdwardLoftus2 @MLongMD @Khanna_S @IBDMD

Great work coming from the #IBD groups at @MayoClinicFLGIH @AHNGastro in collaboration in @APandT @akMD03 @JessPetrovMD @FarrayeIBD @JHashashMD @GKochharMD 🔥 topic #GLP1 in #IBD ➡️ no difference in steroid use but ⬇️ risk of surgery in #CD and #UC rb.gy/591zna

Join us for Mayo Clinic Updates in Inflammatory Bowel Disease 2024 Updates in the diagnosis + management of #IBD & related complications Open to physicians, APPs, nurses, pharmacists, learners   Sept 28 7AM-6PM Mayo Clinic Florida Jacksonville, Florida   Visit ce.mayo.edu/ibd2024 for details and registration

🔎 ACG Case Reports Journal 🔍 Sirolimus Use in Refractory Crohn's Disease Siu, et al. 👉 bit.ly/45Clnh7 @RSiuMD @ChristianKarime @JHashashMD @ibdgijami @FarrayeIBD @KhushbooSGala @VibhuC_MD #GIfellows

Excited to be returning to Boston to speak at the upcoming #BostonIBD conference about the latest advancements in #IBDResearch and treatment. Looking forward to connecting with faculty and attendees. Hope to see you there! cme.bu.edu/BostonIBD24 @BU_CME

Join @FarrayeIBD and @MLongMD as we discuss the Best of ECCO Part 3. IBD Drive Time: The Best of ECCO WIth Dr Frank Farraye hmpgloballearningnetwork.com/site/aibdnet/p…